Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

The company’s revenue from operations saw a significant decline of 39%, dropping to ₹12.9 Crore from ₹21.2 Crore in the ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Shares of Sun Pharmaceutical Industries declined five per cent to Rs 1,766.15 in early trade on the BSE on Monday following a ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Sun Pharmaceutical Industries is likely to attract attention on Monday (November 4) following a recent US court ruling that ...

Sun Pharmaceuticals , India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on ...

Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.

Sun Pharmaceutical Industries slipped 4.30% to 1,778.85 after the US District Court of New Jersey has decided to grant a preliminary injunction delaying the launch of Leqselvi (Baldness treatment) in ...